The route of administration dictates the immunogenicity of peptide-based cancer vaccines in mice

Role of MDA5 and interferon-I in dendritic cells for T cell expansion by anti-tumor peptide vaccines in mice

(2018) Hussein Sultan et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Sustained Persistence of IL2 Signaling Enhances the Antitumor Effect of Peptide Vaccines through T-cell Expansion and Preventing PD-1 Inhibition

(2018) Hussein Sultan et al.   Cancer Immunology Research

Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

(2017) Ugur Sahin et al.   NATURE

An immunogenic personal neoantigen vaccine for patients with melanoma

(2017) Patrick A. Ott et al.   NATURE

Designing therapeutic cancer vaccines by mimicking viral infections

(2016) Hussein Sultan et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses

(2016) Takumi Kumai et al.   Cancer Immunology Research

Therapeutic cancer vaccines

(2015) Cornelis J.M. Melief et al.   JOURNAL OF CLINICAL INVESTIGATION

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

IgG-Mediated Anaphylaxis to a Synthetic Long Peptide Vaccine Containing a B Cell Epitope Can Be Avoided by Slow-Release Formulation

(2014) E. D. Quakkelaar et al.   JOURNAL OF IMMUNOLOGY

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

(2014) Matthew M. Gubin et al.   NATURE

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

T-Cell and NK-Cell Infiltration into Solid Tumors: A Key Limiting Factor for Efficacious Cancer Immunotherapy

(2014) I. Melero et al.   Cancer Discovery

Polyinosinic-Polycytidylic Acid Is the Most Effective TLR Adjuvant for SIV Gag Protein-Induced T Cell Responses In Nonhuman Primates

(2013) H. Park et al.   JOURNAL OF IMMUNOLOGY

Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion

(2013) Yared Hailemichael et al.   NATURE MEDICINE

Transnuclear TRP1-Specific CD8 T Cells with High or Low Affinity TCRs Show Equivalent Antitumor Activity

(2013) S. K. Dougan et al.   Cancer Immunology Research

BiVax: a peptide/poly-IC subunit vaccine that mimics an acute infection elicits vast and effective anti-tumor CD8 T-cell responses

(2012) Hyun-Il Cho et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

TriVax-HPV: an improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers

(2012) Kelly Barrios et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting

(2012) Hirokazu Matsushita et al.   NATURE

The Present and Future of Peptide Vaccines for Cancer

(2011) Craig L. Slingluff   CANCER JOURNAL

A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma

(2010) M. R. Rosenfeld et al.   NEURO-ONCOLOGY

Optimized Peptide Vaccines Eliciting Extensive CD8 T-Cell Responses with Therapeutic Antitumor Effects

(2009) H.-I. Cho et al.   CANCER RESEARCH

Self-antigen–specific CD8+T cell precursor frequency determines the quality of the antitumor immune response

(2009) Gabrielle A. Rizzuto et al.   JOURNAL OF EXPERIMENTAL MEDICINE

A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05)

(2008) Nicholas Butowski et al.   JOURNAL OF NEURO-ONCOLOGY